NCT07400198
Gait and Bone Health in SMA
Recruiting · Not specified · Jacqueline Montes · registry updated 2026-03-18
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
The objective of this study is to understand how spatiotemporal and kinetic gait parameters are associated with bone health in pwSMA who are receiving DMT. We hypothesize that gait parameters are associated with BMD and can determine fracture risk in pwSMA. This is an observational study that involves one in-clinic visit (approximately 3 hours) with remote follow-up visits (approximately 15 minutes) every 3 months for 1 year to collect fracture and medical history. Each of the assessments included in this study are non-interventional and are not intended as a treatment nor are they at the level of standard of care.
Inclusion
- Confirmed diagnosis of 5qSMA
- Between 8 and 50 years of age
- Able to walk 10 meters without support or an assistive device
- All participants who meet the inclusion criteria regardless of treatment status will be included, including those on adjuvant therapies, whether investigational or approved
Exclusion
- Injury or surgery within previous 3 months that would impact ability to perform in-clinic gait assessments
- Unwilling or unable to comply with all study procedures
- Age less than 8 or over 50 years